Olsson, B;
Blennow, K;
Zetterberg, H;
(2016)
The clinical value of fluid biomarkers for dementia diagnosis reply.
[Letter].
Lancet Neurology
, 15
(12)
pp. 1204-1205.
10.1016/S1474-4422(16)30247-2.
Preview |
Text
Zetterberg_Olsson.pdf - Accepted Version Download (140kB) | Preview |
Abstract
We would like to thank Suzanne Dyer and colleagues for their comments about our Article.1 We would also like to clarify that the Cochrane Review2 excluded most of the studies that were included in our meta-analysis, which reported a highly consistent pattern of Alzheimer's disease-related biomarker changes (increased total tau, phosphorylated tau, and neurofilament light protein, and decreased amyloid β42 concentrations in CSF), that not only manifest in Alzheimer's disease but also in patients with mild cognitive impairment. These biomarkers are backed by solid evidence regarding the types of pathologies they reflect; they were not derived from random screens (eg, proteomics or multiplex protein panels) and have been validated with both neuropathology and amyloid PET findings.3 Thus, there is, in our view, no risk that the consistent findings in the scientific literature are spurious to some kind of confounder that would be present in some patients seeking medical advice at memory clinics.
Archive Staff Only
 |
View Item |
